iA Global Asset Management Inc. Boosts Stake in Bristol Myers Squibb Company $BMY

iA Global Asset Management Inc. lifted its position in Bristol Myers Squibb Company (NYSE:BMY) by 20.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 158,680 shares of the biopharmaceutical company’s stock after purchasing an additional 27,347 shares during the quarter. iA Global Asset Management Inc.’s holdings in Bristol Myers Squibb were worth $7,156,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Ridgewood Investments LLC grew its position in shares of Bristol Myers Squibb by 18.7% during the third quarter. Ridgewood Investments LLC now owns 48,602 shares of the biopharmaceutical company’s stock worth $2,192,000 after acquiring an additional 7,656 shares during the last quarter. Naples Global Advisors LLC boosted its stake in Bristol Myers Squibb by 2.7% during the 3rd quarter. Naples Global Advisors LLC now owns 81,643 shares of the biopharmaceutical company’s stock worth $3,682,000 after purchasing an additional 2,130 shares during the period. Leelyn Smith LLC grew its position in Bristol Myers Squibb by 12.1% during the 3rd quarter. Leelyn Smith LLC now owns 55,004 shares of the biopharmaceutical company’s stock worth $2,481,000 after purchasing an additional 5,956 shares during the last quarter. Covestor Ltd increased its stake in Bristol Myers Squibb by 23.9% in the third quarter. Covestor Ltd now owns 4,484 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 864 shares during the period. Finally, Hudson Edge Investment Partners Inc. raised its holdings in shares of Bristol Myers Squibb by 10.2% in the third quarter. Hudson Edge Investment Partners Inc. now owns 144,968 shares of the biopharmaceutical company’s stock valued at $6,538,000 after buying an additional 13,394 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $54.61 on Friday. The stock has a market capitalization of $111.17 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 0.17 and a beta of 0.29. The business’s 50 day moving average is $52.57 and its two-hundred day moving average is $48.39. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. During the same period last year, the firm earned $1.80 EPS. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. The ex-dividend date is Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is presently 85.14%.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY struck a sizable collaboration and exclusive license deal with Janux Therapeutics (worth up to ~$800M), signaling near‑term external innovation that could bolster BMY’s oncology pipeline and near‑term partnering upside. Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million
• Positive Sentiment: BMY and BioNTech advanced a Phase 3 lung‑cancer program for pumitamig, a potential new competitor to Keytruda — a successful readout would be material to oncology revenue upside. Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial
• Positive Sentiment: BMY reported progress in a China mesothelioma trial for Opdivo + Yervoy, which signals additional oncology label/market expansion opportunities in a large market. Bristol Myers Squibb Advances Opdivo/Yervoy in China Mesothelioma Trial, Signaling New Oncology Upside
• Positive Sentiment: BMY announced a collaboration with Microsoft to develop AI‑driven early detection tools for lung cancer — a strategic move that could accelerate diagnostics-linked R&D and potential data/technology synergies. Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
• Positive Sentiment: Analysts at UBS turned more constructive on biotech/pharma, including BMY exposure, which supports investor sentiment around sector recovery and dividend stability. Bristol-Myers (BMY): UBS turns bullish as biotech and pharma show signs of a recovery
• Neutral Sentiment: Coverage pieces are re‑evaluating BMY’s valuation and pipeline after the Microsoft pact and Camzyos trial news — useful context but not an immediate earnings swing. A Look At Bristol Myers Squibb (BMY) Valuation After New Microsoft AI Pact And Camzyos Trial Results
• Neutral Sentiment: Analyst action: Citi placed BMY at a Hold, tempering upside expectations from some investors even as clinical headlines roll in. Bristol-Myers Squibb (BMY) Receives a Hold from Citi
• Negative Sentiment: An analyst lowered Q1 EPS estimates for BMY, adding short‑term earnings pressure and a reason for cautious positioning ahead of upcoming quarterly/clinical readouts. Q1 EPS Estimate for Bristol Myers Squibb Lowered by Analyst
• Neutral Sentiment: Stock commentary noting “mixed returns and pipeline developments” flags that while R&D catalysts are meaningful, execution risk and valuation remain focal for investors. Reassessing Bristol Myers Squibb (BMY) After Mixed Returns And Product Pipeline Developments

Wall Street Analyst Weigh In

BMY has been the topic of a number of research reports. UBS Group raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price target for the stock from $46.00 to $65.00 in a report on Wednesday, January 7th. Morgan Stanley reaffirmed an “underweight” rating and set a $37.00 price objective (up from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Guggenheim reiterated a “buy” rating on shares of Bristol Myers Squibb in a research note on Tuesday, December 23rd. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Leerink Partners increased their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Seven equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus price target of $56.86.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.